Memcine Pharmaceuticals, Inc.
Kate Holt
BioVentures Center
2500 Crosspark Rd., E110
Coralville, IA 52241
(319) 333-8562

<< Back to the listing

Memcine Pharmaceuticals, Inc. 

Memcine is developing ImmunoplexTM, the next generation vaccine platform technology aimed at transforming the $26B global vaccine market.  ImmunoplexTM is optimized for mucosal delivery, and as such, promises to deliver cost effective needle-free vaccines.  Proof-of-concept has been achieved in several preclinical rodent models, including Hepatitis B virus and influenza virus.  Early results in a breast cancer murine model suggest that ImmunoplexTM may function as a vaccine immunotherapy in cancer patients.  Memcine’s business strategy is to function as a discovery engine and out-license by field and territory for both human and veterinary vaccine applications. 

UI Research
BioVentures Center
Technology Innovation Center
Technology Transfer
IOWA Centers for Enterprise
Available Land & Buildings
News & Events
Download Center
Contact Us